Skip to content

Advertisement

  • Research
  • Open Access

Cost-effectiveness of human papillomavirus vaccination in Germany

  • 1Email authorView ORCID ID profile,
  • 2,
  • 2, 3, 4,
  • 5, 6,
  • 7,
  • 8,
  • 9,
  • 9,
  • 10 and
  • 1
Cost Effectiveness and Resource Allocation201715:18

https://doi.org/10.1186/s12962-017-0080-9

©  The Author(s) 2017

  • Received: 8 September 2016
  • Accepted: 23 August 2017
  • Published:

Abstract

Background

The aim of this study was to assess the cost-effectiveness of human papillomavirus (HPV) vaccination in addition to the current cervical cancer screening programme in Germany using a dynamic transmission model.

Methods

Based on a mathematical model simulating the transmission dynamics and the natural history of HPV infection and associated diseases (cervical intraepithelial neoplasia, cervical cancer, and genital warts), we estimated the epidemiological and economic consequences of HPV vaccination with both the quadrivalent and bivalent vaccines. In our base case analysis, we assessed the cost-effectiveness of vaccinating 12-year-old girls with a 3-dose schedule. In sensitivity analysis, we also evaluated the use of a 2-dose schedule and assessed the impact of vaccinating boys.

Results

From a health care payer perspective, incremental cost-effectiveness ratios (ICERs) of a 3-dose schedule were €34,249 per quality-adjusted life year (QALY) for the bivalent and €14,711 per QALY for the quadrivalent vaccine. Inclusion of indirect costs decreased ICERs by up to 40%. When adopting a health care payer perspective, ICERs of a 2-dose approach decreased to €19,450 per QALY for the bivalent and to €3645 per QALY for the quadrivalent vaccine. From a societal perspective, a 2-dose approach using the quadrivalent vaccine was a cost-saving strategy while using the bivalent vaccine resulted in an ICER of €13,248 per QALY. Irrespective of the perspective adopted, additional vaccination of boys resulted in ICERs exceeding €50,000 per QALY, except for scenarios with low coverage (20%) in girls.

Conclusions

Our model results suggest that routine HPV vaccination of 12-year-old girls with three doses is likely to be cost-effective in Germany. Due to the additional impact on genital warts, the quadrivalent vaccine appeared to be more cost-effective than the bivalent vaccine. A 2-dose schedule of the quadrivalent vaccine might even lead to cost savings when adopting a societal perspective. The cost-effectiveness of additional vaccination of boys was highly dependent on the coverage in girls.

Keywords

  • HPV
  • Vaccination
  • Economic evaluation
  • Cost-effectiveness
  • Dynamic transmission model
  • Germany

Background

Persistent infection with high-risk (oncogenic) types of human papillomavirus (HPV) is the main cause of cervical cancer and its precursors [1]. Infection with high-risk HPV types can also cause other types of anogenital cancer (i.e. vaginal, vulvar, anal, and penile cancer) and oropharyngeal cancer [2, 3], whereas infection with low-risk (non-oncogenic) HPV types is primarily associated with genital warts [4].

Clinical studies have demonstrated high efficacy of prophylactic HPV vaccines in the prevention of HPV infections, premalignant anogenital lesions (cervical, vaginal, vulvar, and anal lesions), and genital warts [5–7]. In Germany, there are currently three HPV vaccines available to prevent HPV infection and related diseases: a bivalent vaccine (Cervarix®), a quadrivalent vaccine (Gardasil®), and a 9-valent vaccine (Gardasil® 9). All three vaccines protect against the high-risk genotypes 16 and 18, which cause approximately 70% of all cervical cancer cases [8]. The quadrivalent vaccine is additionally directed against the low-risk genotypes 6 and 11, which account for approximately 90% of genital warts [9]. The recently approved 9-valent version of Gardasil® protects against the four strains of the quadrivalent vaccine and five additional high-risk strains (31, 33, 45, 52, and 58). All available vaccines are licensed for use in females and males.

In Germany, routine HPV vaccination with two doses is currently recommended for females aged 9–14 years [10, 11]. However, three doses are necessary when vaccinating adolescent girls aged 15–17 years (due to delayed initiation or series completion) or when the interval between the first and the second dose falls below 6 months. Before August 2014, three HPV vaccine doses were recommended for females aged 12–17 years. Both recommendations have primarily aimed at preventing cervical cancer. Since 1971, a cervical cancer screening programme is implemented in Germany, which is currently based on an annual Pap smear beginning at the age of 20 years.

No independently funded dynamic transmission model analysing the cost-effectiveness of HPV vaccination in the German health care setting, which can support the national decision-making process of the Standing Vaccination Committee (STIKO), has been published yet.

The purpose of this study was threefold: (a) to assess the cost-effectiveness of the bivalent and quadrivalent vaccines in addition to the existing cervical cancer screening programme in Germany using a dynamic transmission model, (b) to quantify the economic impact of switching from a 3-dose to a 2-dose schedule, and (c) to compare our results with findings of previously published studies on the cost-effectiveness of HPV vaccination in Germany.

Methods

Overview

We developed a mathematical model simulating the transmission dynamics and the natural history of HPV infection and associated diseases to evaluate the epidemiological and economic consequences of HPV vaccination in Germany. The age-structured model takes account of the occurrence of cervical intraepithelial neoplasia (CIN), cervical cancer, and genital warts. It was calibrated using German cancer statistics and other data. In the base case analysis, which was conducted from both a health care payer and a societal perspective, HPV vaccination of 12 year old girls in conjunction with the existing cytological screening programme was compared to screening alone. The time horizon was set to 100 years after the introduction of HPV vaccination. Epidemiological and economic parameter estimates were obtained from published literature and supplemented by expert interviews. The model was programmed using the software R. All cost calculations were performed using Microsoft Excel. Details on the methods and data sources used to construct the model are described in the following sections. A more detailed description of the underlying epidemiological model and the corresponding model parameters regarding the transmission of HPV, the natural history of cervical HPV infection, and the simulated screening programme has been published previously [12].

Model structure

The basic model structure combines an age-structured deterministic compartmental model, which simulates the sexual transmission of HPV, with a model that represents the natural history of cervical cancer.

The transmission dynamics are described by a SIRS-model where the population is divided into susceptible individuals (S), infectious individuals (I), and recovered (and therefore immune) individuals (R). Our model considers six groups of viral strains: HPV 16, HPV 18, phylogenetically related high-risk types with potential for cross-protection (HPV 31/33/35/39/45/51/52/56/58/59), other high-risk types without potential for cross-protection, HPV 6/11, and other low-risk types. We neglected any synergistic and antagonistic interactions between different HPV types as multi-strain interactions are subject to controversy.

To estimate the long-term consequences of HPV infection, the transmission model was complemented by a module covering the cervical carcinogenesis. This part of the model includes type-specific health states for having CIN of three grades (CIN 1, CIN 2, or CIN 3), having carcinoma in situ (CIS), and having invasive cervical cancer of different stages according to the International Federation of Gynecology and Obstetrics (FIGO) classification system. CIS and invasive cancer states were further subdivided into undetected and detected disease states. For women who had undergone hysterectomy, only transitions between the susceptible, infected, and immune (recovered) states were permitted. Therefore, with the exception of sexual mixing and background mortality, those women were modelled identically to males who were only allowed to move between the susceptible, infected, and immune states. The occurrence of genital warts in both genders was modelled as an event that was linked with incident infections with low-risk types, but only a proportion of those newly infected individuals were assumed to develop clinical symptoms of genital warts and to seek medical treatment. A simplified flow diagram of the model structure representing the natural history of HPV infection and cervical cancer in women is outlined in Fig. 1.
Fig. 1
Fig. 1

Simplified model structure

(adapted from Horn et al. [12])

Data sources and model inputs

Demographic, behavioural, and transmission parameters

The model population is based on a constant number of one million births per year and the 2008 mortality rates in Germany derived from the Federal Statistical Office. Our model focusses on heterosexual transmission of HPV infection only. We assumed the sexual debut to be at the age of 12 years and divided the sexually active population into ten age groups (12–13, 14–15, 16–17, 18–24, 25–34, 35–44, 45–54, 55–64, 65–74, and 75–100 years) and three sexual activity-based risk groups (low, moderate, and high activity). The proportions of individuals belonging to the different activity classes were 80, 15, and 5% for the low, moderate, and high activity groups, respectively [13]. The mixing patterns between individuals of the different age and risk groups were determined by two mixing parameters. These parameters for the assortativeness of mixing by age and by risk group were set to 0.4 and 0.3, respectively [14]. An assortativeness by age of 0.4 means that 40% of new sexual partners are preferentially chosen from the same age group while the remaining sexual partners are chosen proportionally from all age groups depending on their size. An assortativeness by risk group of 0.3 means that 30% of partners are preferentially chosen within the same sexual activity group while the remaining sexual partners are chosen proportionally from all sexual activity groups depending on their size. As robust German data on patterns of sexual behaviour were lacking, we used data from the transmission model by Zechmeister et al. [15], which had been originally derived from British and Norwegian surveys of sexual behaviour.

Natural history

The initial values of the epidemiological model parameters regarding the natural history of cervical cancer were obtained from the published literature, particularly from previous modelling studies [14, 16–20]. Whereas some parameter values were directly incorporated in our model, other values were derived through calibration. Details on the parameter values used in our model are provided in an article by Horn et al. [12].

Not every HPV infection is followed by the development of a type-specific resistance. Hence, we only allowed a fraction of the infected population to be immune after infection for a certain period of time [21]. The proportion of individuals experiencing a seroconversion was estimated to be 60% [22]. The fraction of seroconverted individuals developing a naturally acquired immunity was estimated to be 30% [23]. Waning of naturally acquired immunity was assumed to be 10% per year resulting in an average type-specific immunity of 10 years.

In our model, the CIS state was subdivided into two compartments as proposed by Insinga et al. [24] to avoid short transition times from CIS to invasive cancer resulting from the exponential distribution.

Screening programme

The screening module of our model was constructed to reflect the current screening practice in Germany. We applied age-specific screening coverage rates that were obtained from German data [25] and assumed the proportion of women who never participate in screening to be 7% as done in other modelling studies [18, 19]. To simulate the future effects of the stepwise increase in screening coverage in Germany during the 1990s and to prevent an overestimation of the vaccine-induced reduction in cervical cancer-related burden of disease, we incorporated historical changes in screening uptake in our model. For this purpose, we combined the current age-specific screening coverage rates with the observed changes in participation in early cancer detection programmes over time [26]. Diagnostic follow-up (including management of abnormal cervical cytology and histology) was modelled by the use of integrated decision trees. The construction of these decision trees was based on clinical guidelines, empirical studies, health economic models, and an interview with members of the German working group on cervical pathology and colposcopy that was conducted explicitly for this purpose.

Vaccination

In the base case scenario, we analysed the cost-effectiveness of vaccinating 12-year-old girls with three doses. Vaccination coverage was assumed to be 50% based on several studies assessing HPV vaccine uptake in Germany [27–32]. In these studies, reported uptake, defined as receipt of at least one HPV vaccine dose, ranged from 30 to 60%. When considering only those females who received the full course of three doses, uptake ranged from 27 to 48%. We assumed completion of the 3-dose series for all girls who initiated vaccination. All analyses were carried out for both the bivalent and quadrivalent vaccines. Vaccine efficacy against HPV 16/18 infection was estimated to be 98% for both vaccines, and vaccine efficacy in preventing HPV 6/11 infection was estimated to be 100% for the quadrivalent vaccine. Cross-protection against non-vaccine oncogenic HPV-types was not considered in the base case scenario but was explored in sensitivity analysis taking the different cross-protection profiles of the vaccines into account. Currently, the maximum duration of vaccine protection is unknown. Clinical efficacy against type-specific infection and associated diseases has been demonstrated up to 9.4 years post-vaccination [33], but long-term persistence of antibody responses has been predicted by statistical modelling of individual antibody data [34, 35]. Taking both the evidence based on limited follow-up of adolescent girls and women in clinical trials and the predictions of statistical models into account, we decided to assume a 10 years lasting initial period of sustained vaccine protection followed by a period of waning immunity using a waning rate of 10% per year. This approach resulted in an average duration of vaccine-induced immunity of 20 years. We separately examined the impact of lifelong protection as well as the influence of administering a booster dose in sensitivity analysis. While in the base case scenario vaccination was restricted to girls, immunisation of boys was assessed in sensitivity analysis. A 2-dose schedule was also examined in sensitivity analysis. All vaccination-related input data are presented in Table 1.
Table 1

Vaccination-related input variables

Parameter

Value

Source

Vaccine efficacy

HPV 16/18 in females

98%

[81, 82]

HPV 6/11 in females (quadrivalent vaccine only)

100%

[83]

HPV 16/18 in males

90.4%

[84]

HPV 6/11 in males (quadrivalent vaccine only)

90.4%

[84]

Cross-protection provided by the quadrivalent vaccine (considered in sensitivity analysis only)

HPV 31/33/35/39/45/51/52/56/58/59

32.5%

[85, 86]

Cross-protection provided by the bivalent vaccine (considered in sensitivity analysis only)

HPV 31/33/35/39/45/51/52/56/58/59

68.4%

[86]

Duration of full protection

10 years

Assumption

Waning (after the duration of full protection)

0.1 per year

Assumption

Vaccination coverage

50%

Assumption

Age at vaccination

12 years

Assumption

Booster vaccination

No booster vaccination in the base case analysis

Assumption

HPV human papillomavirus

Resource utilisation and direct health care costs

Our model takes into account resource use associated with vaccination, screening, management of abnormal cytological screening results, management and treatment of biopsy-confirmed CIN, and treatment of cervical cancer and genital warts. Direct health care costs were calculated considering all relevant cost components that are reimbursed by the statutory health insurance. These components include medication, physician consultations, outpatient diagnostic procedures, laboratory testing, therapeutic appliances and outpatient health care services provided by non-physicians (i.e. medical compression tights and manual lymphatic drainage as part of lymphoedema treatment), and hospitalisations.

Treatment patterns and related resource consumption were mainly derived from clinical guidelines and published studies on the current management of cervical cancer and its precursors [36–39]. Literature-based evidence was supplemented by expert opinion to account for missing data for Germany and variation in clinical practice. For instance, the experts were asked to estimate the stage-specific frequency of utilisation for different outpatient and inpatient treatment procedures of cervical cancer. A total of six expert interviews with gynaecologists were conducted by telephone or in written form. Table 2 gives an overview of the assumed treatment patterns and resource utilisation in the treatment and post-treatment follow-up of cervical cancer.
Table 2

Treatment patterns and resource utilisation in the treatment and post-treatment follow-up of cervical cancer (percentages are average values based on experts’ responses)

Cervical cancer stage (FIGO classification) or treatment phase

Treatment patterns and resource utilisation

FIGO IA1

Conisation

60%

Conisation with pelvic lymph node dissection

10%

Simple hysterectomy

20%

Simple hysterectomy with pelvic lymph node dissection

10%

FIGO IA2

Conisation with pelvic lymph node dissection

20%

Radical trachelectomy with pelvic lymph node dissection

10%

Simple hysterectomy

10%

Simple hysterectomy with pelvic lymph node dissection

60%

FIGO IB1

Radical hysterectomy with pelvic lymph node dissection

64%

Radical hysterectomy with pelvic lymph node dissection and adjuvant chemoradiotherapy

16%

Radical trachelectomy with pelvic lymph node dissection

5%

Chemoradiotherapy

15%

FIGO IB2

Radical hysterectomy with pelvic and paraaortic lymph node dissection

49%

Radical hysterectomy with pelvic and paraaortic lymph node dissection and adjuvant chemoradiotherapy

21%

Chemoradiotherapy

30%

FIGO IIA

Radical hysterectomy with pelvic and paraaortic lymph node dissection

35%

Radical hysterectomy with pelvic and paraaortic lymph node dissection and adjuvant chemoradiotherapy

15%

Chemoradiotherapy

50%

FIGO IIB

Radical hysterectomy with pelvic and paraaortic lymph node dissection

12%

Radical hysterectomy with pelvic and paraaortic lymph node dissection and adjuvant chemoradiotherapy

18%

Chemoradiotherapy

70%

FIGO IIIA

Radical hysterectomy with pelvic and paraaortic lymph node dissection

2%

Radical hysterectomy with pelvic and paraaortic lymph node dissection and adjuvant chemoradiotherapy

8%

Chemoradiotherapy

90%

FIGO IIIB

Radical hysterectomy with pelvic and paraaortic lymph node dissection

2%

Radical hysterectomy with pelvic and paraaortic lymph node dissection and adjuvant chemoradiotherapy

8%

Chemoradiotherapy

90%

FIGO IVA

Radical hysterectomy with pelvic and paraaortic lymph node dissection

2%

Radical hysterectomy with pelvic and paraaortic lymph node dissection and adjuvant chemoradiotherapy

8%

Chemoradiotherapy

80%

Exenteration

2%

Exenteration and adjuvant chemoradiotherapy

8%

FIGO IVB

Chemoradiotherapy

40%

Palliative chemotherapy

60%

Post-treatment follow-up

Outpatient visits, Pap-smears, and pelvic and abdominal ultrasonography

100%

Hormone replacement therapy (women <50 years)

50%

Manual lymphatic drainage and medical compression tights

10–30%

FIGO International Federation of Gynecology and Obstetrics

Most unit costs were based on official German price lists, fee scales, or catalogues. Vaccine prices and drug costs were obtained from the pharmaceutical database LAUER-TAXE® [40]. The cost per dose of both vaccines was estimated at €150.41. The mean vaccine administration fee was calculated to be €7.50 per dose, based on a review of the immunisation fee scales of all regional Associations of Statutory Insurance Physicians in Germany. Charges for outpatient visits as well as outpatient diagnostic and treatment procedures were based on the physician fee scale (Einheitlicher Bewertungsmaßstab, EBM) of the statutory health insurance. Hospitalisation costs were retrieved from the German diagnosis-related group (DRG) catalogue using a base rate of €2935.78 and the cost weights of various DRGs (N01A, N01E, N03B, N09Z, N15Z, and N60A). Costs of inpatient palliative care and treatment were calculated assuming a length of stay of 30 days and combining the DRG N60B with a supplementary fee for palliative care (ZE60.01). All direct costs were adjusted for patient co-payments. Cost estimates for treating CIN 3 and CIS were taken from a German resource use study providing intervention costs associated with a PAP IV diagnosis of the Munich Cytological Classification, which corresponds to severe dysplasia and CIS [41]. Costs for treating genital warts were based on own calculations using data from a German cost-of-illness study [42]. All costs are reported in 2010 euros. Where 2010 prices were not available, prices were inflated to 2010 values using the German consumer price index (CPI). The base case values of the aggregated direct health care costs are summarised in Table 3.
Table 3

Direct health care costs

Parameter

Direct costs (€, 2010 price level)

Vaccination costs

 Vaccine (initial series of 3 doses)

451.23

 Administration (initial series of 3 doses)

22.50

 Booster shot (per dose)

150.41

 Administration of booster shot (per dose)

7.50

Costs of screening, management of abnormal cytological screening results, and observational follow-up of CIN 1 and CIN 2

 Cytological screening (Pap smear)

25.23

 Follow-up smear (including quarterly Gynaecologist’s fee and optional colposcopy)

≤59 years

20.15

60+ years

20.33

 HPV test (including quarterly Gynaecologist’s fee)

≤59 years

44.77

60+ years

44.94

 HPV test and follow-up smear (including quarterly Gynaecologist’s fee)

≤59 years

50.55

60+ years

50.73

 Colposcopy (including quarterly Gynaecologist’s fee)

≤59 years

14.37

60+ years

14.54

 Biopsy and histology

129.47

Costs of CIN/CIS treatment and post-treatment follow-up

 Conisation of the cervix (CIN 1 and CIN 2)

≤39 years

525.05

40–59 years

531.22

60+ years

534.17

 Treatment of CIN 3 and CIS

1621.53

 Post-treatment follow-up of CIN/CIS (year 1 and 2 after treatment)

≤59 years

70.71

60+ years

71.06

Costs of cervical cancer treatment and post-treatment follow-up

 Diagnostics of symptom-detected cervical cancer

≤59 years

323.03

60+ years

324.08

 Diagnostics of screen-detected cervical cancer

≤59 years

179.18

60+ years

180.06

 Treatment of cervical cancer (FIGO I)

≤59 years

7586.98

60+ years

7591.22

 Treatment of cervical cancer (FIGO II)

≤59 years

11,455.22

60+ years

11,456.94

 Treatment of cervical cancer (FIGO III)

≤59 years

12,380.21

60+ years

12,380.70

 Treatment of cervical cancer (FIGO IV)

≤59 years

10,615.72

60+ years

10,616.21

 Post-treatment follow-up of cervical cancer (year 1 after treatment)

≤49 years

841.53

50–59 years

835.65

60+ years

836.35

 Post-treatment follow-up of cervical cancer (year 2 after treatment)

≤49 years

428.13

50–59 years

422.25

60+ years

422.95

 Post-treatment follow-up of cervical cancer (year 3 after treatment)

≤49 years

352.42

50–59 years

346.54

60+ years

347.24

 Post-treatment follow-up of cervical cancer (year 4 and 5 after treatment)

≤49 years

282.50

50–59 years

276.62

60+ years

276.97

 Post-treatment follow-up of cervical cancer (from year 6 after treatment onwards)

≤49 years

262.35

50–59 years

256.47

60+ years

256.65

 Inpatient palliative care and treatment

7518.09

Costs of genital warts treatment

 Treatment of genital warts in females

572.14

 Treatment of genital warts in males

396.69

CIN cervical intraepithelial neoplasia, CIS carcinoma in situ, FIGO International Federation of Gynecology and Obstetrics

Indirect costs

Indirect costs in terms of production losses were considered when adopting a societal perspective. Data on absence from work due to HPV-associated illness were obtained from the statistics of a German sickness fund [43] using year 2008 information. Indirect costs were calculated by the friction cost approach assuming the friction period equal to the average duration of a vacant job position. According to a report of the Federal Employment Agency [44], this period was assumed to be 63 days. Cost per work day lost was estimated at €85.13 using 2010 data on monetary compensation and number of employees in Germany from the Federal Statistical Office [45]. Indirect costs due to CIN and cervical cancer were weighted by age-specific employment rates of women to avoid an overestimation of the production losses. All indirect cost inputs are summarised in Table 4.
Table 4

Indirect costs

Parameter

Average absence from work (days)a

Indirect costs (€, 2010 price level)b

Treatment of CIN 1 and CIN 2

15.9

15–19 years

336.50

20–24 years

835.26

25–29 years

965.33

30–34 years

977.31

35–39 years

1009.89

40–44 years

1063.18

45–49 years

1060.82

50–54 years

1010.30

55–59 years

853.97

60–64 years

410.89

Treatment of CIN 3 and CIS

21.3

15–19 years

450.79

20–24 years

1118.93

25–29 years

1293.18

30–34 years

1309.23

35–39 years

1352.87

40–44 years

1424.25

45–49 years

1421.10

50–54 years

1353.42

55–59 years

1144.00

60–64 years

550.44

Treatment of cervical cancer (all FIGO stages)

44.4

15–19 years

939.67

20–24 years

2332.42

25–29 years

2695.65

30–34 years

2729.11

35–39 years

2820.06

40–44 years

2968.87

45–49 years

2962.30

50–54 years

2821.22

55–59 years

2384.68

60–64 years

1147.39

Death due to cervical cancer (all FIGO stages)

63 (friction period)

15–19 years

1333.31

20–24 years

3309.52

25–29 years

3824.91

30–34 years

3872.38

35–39 years

4001.44

40–44 years

4212.58

45–49 years

4203.26

50–54 years

4003.08

55–59 years

3383.67

60–64 years

1628.06

Treatment of genital warts in females

7.7

15–64 years

30.81c

Treatment of genital warts in males

8.7

15–64 years

28.14c

CIN cervical intraepithelial neoplasia, CIS carcinoma in situ, FIGO International Federation of Gynecology and Obstetrics

aAverage duration of absence from work in patients who missed work because of illness

bWeighted by age-specific employment rates of women

cNot weighted by age-specific employment rates as the fraction of genital warts patients who missed work was estimated directly on the basis of a German study [42]

Health state utilities

In the absence of utility values that are specific to Germany, the data for calculating quality-adjusted life years (QALYs) were taken from the international literature and previous health economic models. These studies applied different methods for eliciting QALY weights including the use of the EQ-5D questionnaire [46], the time trade-off technique [47], and an expert-based application of the Health Utility Index (HUI) Mark II [48]. The selection of utility values was guided by the model structure. The utility values used in our model are presented in Table 5. We assumed the baseline utility value of normal health to be 1.0. Estimates for the duration of reductions in quality of life were mainly based on expert opinion. QALY losses associated with Pap smear-based screening and diagnostic follow-up of cytological and histological results were not considered in our modelling approach.
Table 5

Utility values

Health state

Utility value

Duration

Source

Treatment of CIN 1

0.91

2 months

[47]

Treatment of CIN 2

0.87

2 months

[47]

Treatment of CIN 3

0.87

2 months

[47]

Treatment of CIS

0.80

2 months

[48]

Follow-up of CIS

0.97

1.8 years (22 months)

[48]

Treatment of FIGO I

0.65

6 months

[87]

Follow-up of FIGO I

0.97

Up to 4.5 years (54 months)

[48, 87]

Treatment of FIGO II

0.56

6 months

[87]

Follow-up of FIGO II

0.90

Up to 4.5 years (54 months)

[48, 87]

Treatment of FIGO III

0.56

6 months

[87]

Follow-up of FIGO III

0.90

Up to 4.5 years (54 months)

[48, 87]

Treatment of FIGO IV

0.48

6 months

[88]

Follow-up of FIGO IV

0.62

Up to 4.5 years (54 months)

[48, 87]

Palliative care

0.29

1 month

[89]

Treatment of genital warts

0.93

2 months

[46, 48] (mean value of both sources)

CIN cervical intraepithelial neoplasia, CIS carcinoma in situ, FIGO International Federation of Gynecology and Obstetrics

Discounting

In the base case analysis, future costs and health effects were discounted at an annual rate of 3% as recommended by guidelines of the Institute for Quality and Efficiency in Health Care [49] and the STIKO [10]. Other German recommendations on health economic evaluation, also referred to as Hanover Consensus, favour a discount rate of 5% [50], which was considered in sensitivity analysis. In addition, we assessed the impact of differential discounting (3% for costs and 1.5% for health effects) [51].

Analytic strategy and sensitivity analysis

To determine the cost-effectiveness of the introduction of HPV vaccination in Germany, we calculated incremental cost-effectiveness ratios (ICERs) using life years (LYs) gained and QALYs gained as outcome measures. The base case analysis was carried out from the German health care payer perspective, which is the perspective of the statutory health insurance funds (taking account of reimbursed direct costs only), and from the societal perspective (considering reimbursed direct costs as well as indirect costs). Patient co-payments were not included in both perspectives since not all relevant sources provided sufficient details on that aspect.

We evaluated the long-term health and economic effects of vaccinating 12-year-old girls against HPV alongside the current cytology-based cervical cancer screening programme compared to an exclusive continuation of the cytological screening programme. Deterministic sensitivity analyses were performed to test the robustness of the results to changes in model input data and assumptions. The impact of varying single model parameters was examined by one-way sensitivity analyses. Parameters varied were characteristics of the vaccination programme, costs, utilities, and the discount rate. Furthermore, we assessed the implication of incorporating vaccine-specific cross-protection and evaluated the additional impact of vaccinating boys. Since a 2-dose schedule showed equivalent antibody response and similar efficacy to the standard 3-dose regimen [52–54], we also analysed the cost-effectiveness of administering only two doses at the age of 12 years assuming the same level of protection. Multivariate sensitivity analyses were carried out in terms of best-case (6/11/16/18 efficacy: 100%; vaccine-specific cross-protection: 32.5 or 68.4%; lifelong protection; 20% increase in screening and treatment cost; 20% increase in quality of life detriments; societal perspective) and worst-case (6/11/16/18 efficacy: 80%; no cross-protection; average duration of protection: 15 years; 20% decrease in screening and treatment cost; 20% decrease in quality of life detriments; health care payer perspective) analyses.

Model calibration and validation

Model calibration is the process of adjusting input parameter values until the simulation output matches empirical data. Our model was calibrated to reflect observations on age-specific prevalence of HPV infection [55–59], age-specific prevalence of CIN [60], age-specific incidence and mortality of cervical cancer [61], as well as HPV type-distribution in different cervical disease states [57, 62–65]. When data for Germany were not available, we used data from other countries. The modification of parameter values and the subsequent comparison of the simulation results with the observed data were performed manually. Furthermore, we used age-specific adjustment factors for four groups of parameters (progression probabilities of cancer, regression probabilities, detection of cancer by symptoms, and mortality of cervical cancer) to achieve a better fit to the observed data. More details regarding both the model calibration process and the results of the model validation have been previously published [12].

Systematic literature review

We performed a systematic literature review to compare our results with findings of previously published studies on the cost-effectiveness of HPV vaccination in Germany. A PubMed-based literature search was conducted using the following search terms: (“HPV” OR “human papillomavirus”) AND (“vaccine” OR “vaccination” OR “immunisation” OR “immunization”) AND (“cost-effectiveness” OR “economic”) AND “Germany”. This search was complemented by scanning reference lists of previously identified full-text articles. A study was included if it met the following criteria: (i) it was an economic evaluation of HPV vaccination in Germany, (ii) it was conducted from a health care payer or a societal perspective, (iii) it was written in English or German, and (iv) it was published as a full-text article.

Results

Public health impact and costs

The continuation of the current cytology-based screening programme without additional HPV vaccination led to approximately 271,000 cervical cancer cases and about 78,000 cervical cancer deaths when considering a 100-year time horizon. In the same period, low-risk HPV infections caused about 10 million cases of genital warts. In our model, even without HPV vaccination, cervical cancer incidence decreased during the first years of the simulated time horizon, which was related to increased screening coverage in the past. Discounted direct costs were €15.4 billion for the scenario without vaccination. More than 60% of these costs were incurred by screening and related follow-up procedures.

With implemented HPV vaccination, our model projected about 171,000 cervical cancer cases and about 54,000 cervical cancer deaths. This means that supplementing the current screening practice with vaccination of 12-year-old girls with an assumed coverage of 50% prevented approximately 100,000 cervical cancer cases and 24,000 deaths over a time horizon of 100 years. These figures correspond to a 37% reduction in cervical cancer and a 30% reduction in cervical cancer mortality. Vaccination with the quadrivalent vaccine was additionally associated with an overall reduction in genital warts of 88%. About 40% of all prevented cases of genital warts were prevented in males due to herd effects. Expected vaccination costs were €3.5 billion. Overall direct costs (compared to screening only) increased by €2.8 and €1.6 billion for the bivalent and the quadrivalent vaccine, respectively. Table 6 shows the discounted costs considering a 100-year time horizon.
Table 6

Discounted costs over a 100-year time horizon

Discounted costs (€ in thousands)

No vaccination

Bivalent vaccination

Quadrivalent vaccination

Direct costs

 Vaccine (3 doses)

0

3,461,711

3,461,711

 Vaccine administration (3 doses)

0

172,614

172,614

 Screening

8,825,905

8,829,506

8,829,506

 Diagnostic follow-up of abnormal cytological screening results and observational management of CIN 1 and CIN 2

1,481,795

1,370,223

1,349,669

 Treatment of CIN

1,739,325

1,387,470

1,349,167

 Treatment of CIS

498,381

347,349

347,349

 Treatment of cervical cancer

1,233,413

1,013,599

1,013,599

 Treatment of genital warts in females

1,093,366

1,093,360

337,162

 Treatment of genital warts in males

556,932

556,924

178,880

 Total direct costs

15,429,116

18,232,756

17,039,658

Indirect costs (due to work loss)

 Treatment of CIN

1,978,965

1,618,578

1,566,941

 Treatment of CIS

338,862

234,758

234,758

 Treatment of cervical cancer

198,247

154,987

154,987

 Treatment of genital warts in females

58,878

58,878

18,156

 Treatment of genital warts in males

39,507

39,507

12,689

 Total indirect costs

2,614,460

2,106,708

1,987,532

Total costs

 Total direct and indirect costs

18,043,576

20,339,463

19,027,190

CIN cervical intraepithelial neoplasia, CIS carcinoma in situ

Cost-effectiveness

Under base case assumptions, the discounted ICERs of a 3-dose schedule were €53,807 per LY and €34,249 per QALY for the bivalent vaccine and €30,910 per LY and €14,711 per QALY for the quadrivalent vaccine when adopting a health care payer perspective. Inclusion of indirect costs decreased the ICERs to €28,047 and €8984 per QALY for the bivalent and the quadrivalent vaccine, respectively. Cost-effectiveness results of the base case analysis are summarised in Table 7.
Table 7

Base case cost-effectiveness results (3-dose schedule)

Discounted costs (€), health outcomes and ICERs

No vaccination

Bivalent vaccination

Quadrivalent vaccination

Direct costs

15,429,115,908

18,232,755,877

17,039,657,688

Incremental direct costsa

–

2,803,639,969

1,610,541,780

Direct and indirect costs

18,043,576,056

20,339,463,474

19,027,189,752

Incremental total costsa

–

2,295,887,418

983,613,696

LYs lost

377,884

325,779

325,779

Incremental LYs gaineda

–

52,105

52,105

QALYs lost

547,617

465,757

438,136

Incremental QALYs gaineda

–

81,860

109,481

ICER (€/LY), health care payer perspective

–

53,807

30,910

ICER (€/LY), societal perspective

–

44,063

18,878

ICER (€/QALY), health care payer perspective

–

34,249

14,711

ICER (€/QALY), societal perspective

–

28,047

8984

ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, LY life year

aCompared to no vaccination

Sensitivity analysis

Model results were highly sensitive to assumptions about the discount rate and the vaccination age. Vaccinating 16-year-old girls was more cost-effective than vaccinating 12-year-old girls as long as no lifelong protection was assumed. Changes in duration of protection (minimum duration: 10 years of stable protection combined with instant waning of protection afterwards; maximum duration: lifelong protection) had a minor (quadrivalent vaccine) to moderate (bivalent vaccine) impact on the economic results. ICERs increased with increasing coverage due to the combination of diminishing marginal benefit of vaccine-induced protection in the population and linearly increasing vaccination cost. In scenarios with low coverage (≤20%), the use of the quadrivalent vaccine led to cost savings from a societal perspective. However, a low coverage was also associated with fewer prevented cases of cervical cancer (20% coverage: 47,000 prevented cases; 10% coverage: 24,000 prevented cases). Consideration of vaccine-specific cross-protection benefits yielded ICERs of €24,576 per QALY (at an estimated reduction in cervical cancer cases of 119,000) for the bivalent vaccine and €11,429 per QALY (at approximately 113,000 prevented cervical cancer cases) for the quadrivalent vaccine when taking a health care payer perspective. Figure 2 shows the results of several one-way sensitivity analyses using the example of the quadrivalent vaccine with a 3-dose schedule.
Fig. 2
Fig. 2

Results of one-way sensitivity analyses for the quadrivalent vaccine (3-dose schedule, health care payer perspective). Black bars represent the upper bounds, and grey bars represent the lower bounds

In the best case scenario of the 3-dose schedule (6/11/16/18 efficacy: 100%; vaccine-specific cross-protection: 32.5 or 68.4%; lifelong protection; 20% increase in screening and treatment cost; 20% increase in quality of life detriments; societal perspective), about 130,000 cervical cancer cases were prevented, and ICERs decreased to €11,156 per QALY for the bivalent vaccine and €154 per QALY for the quadrivalent vaccine. In the worst case scenario of the 3-dose schedule (6/11/16/18 efficacy: 80%; no cross-protection; average duration of protection: 15 years; 20% decrease in screening and treatment cost; 20% decrease in quality of life detriments; health care payer perspective), about 80,000 cervical cancer cases were prevented and ICERs increased to €50,300 per QALY for the bivalent vaccine and €26,532 per QALY for the quadrivalent vaccine.

If the introduction of HPV vaccination was accompanied by an increase of the screening interval for all age cohorts (regardless of whether they received vaccination or not), cost offsets came along with net QALY losses (i.e. ICERs were located in the south-west quadrant of the cost-effectiveness plane) when compared to the existing screening practice and no vaccination.

A 2-dose schedule led to ICERs of €19,450 per QALY for the bivalent vaccine and €3645 per QALY for the quadrivalent vaccine when taking a health care payer perspective. When adopting a societal perspective, the use of the quadrivalent vaccine with a 2-dose approach appeared to be a cost-saving strategy and the ICER of a 2-dose schedule using the bivalent vaccine decreased to €13,248 per QALY.

Using base case assumptions for vaccinating girls (3-dose schedule with 50% coverage), additional vaccination of 12-year-old boys with three doses and a coverage of 50% resulted in ICERs of €130,449 per QALY for the bivalent vaccine and €117,240 per QALY for the quadrivalent vaccine from a health care payer perspective when compared with vaccinating girls alone. Assuming a low coverage in girls (20%), the cost per QALY of vaccinating boys at a similar coverage level (20%) decreased to €57,024 for the bivalent vaccine and to €37,985 for the quadrivalent vaccine. Assuming a high coverage in girls (80%), additional vaccination of boys (regardless of the coverage level) resulted in ICERs of more than €400,000 per QALY for both vaccines. When using a 2-dose schedule and assuming that two doses are as effective as three doses, ICERs of vaccinating boys remained above €50,000 and €200,000 per QALY in scenarios with moderate and high coverage in girls, respectively. Results of additional vaccination of boys with two or three doses are summarised in Table 8.
Table 8

Cost-effectiveness of vaccinating boys and girls compared with vaccinating girls alone

Vaccination strategy

Comparator (coverage in 12-year-old girls, no vaccination of boys), %

Incremental cases prevented (undiscounted)

ICER (€/QALY)

Bivalent vaccination

Quadrivalent vaccination

Coverage in 12-year-old girls, %

Coverage in 12-year-old boys, %

Cervical cancer

Cervical cancer death

Health care payer perspective

Societal perspective

Health care payer perspective

Societal perspective

2 doses

3 doses

2 doses

3 doses

2 doses

3 doses

2 doses

3 doses

50 (base case)

0 (base case)

0 (base case)

99,914

23,703

19,450

34,249

13,248

28,047

3645

14,711

Cost-saving

8984

50

20

50

16,899

4396

67,129

105,794

61,077

99,742

58,549

94,186

52,648

88,284

50

50

50

32,923

8628

83,602

130,449

77,607

124,453

73,973

117,240

68,118

111,386

50

80

50

37,335

9906

110,977

171,424

105,091

165,538

98,369

153,849

92,625

148,105

20

0

0

46,844

10,815

15,659

28,568

9410

22,318

Cost-saving

3387

Cost-saving

Cost-saving

20

20

20

28,308

7110

34,669

57,024

28,663

51,019

19,892

37,985

14,223

32,316

20

50

20

68,041

17,040

37,066

60,682

30,959

54,574

26,478

46,965

20,617

41,104

20

80

20

87,611

22,065

46,525

74,844

40,440

68,758

36,033

61,027

30,164

55,158

80

0

0

133,226

32,295

25,028

42,605

18,873

36,450

10,562

24,412

4798

18,648

80

20

80

2157

658

313,627

475,013

308,346

469,732

269,103

410,286

263,974

405,157

80

50

80

4365

1332

364,237

550,917

358,953

545,633

311,264

473,605

306,138

468,478

80

80

80

5934

1809

413,018

624,085

407,724

618,790

352,012

534,785

346,880

529,653

ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year

Systematic literature review of previously published economic evaluations of HPV vaccination in Germany

The PubMed search resulted in 17 articles published before June 2016, of which three met the inclusion criteria [66–68]. One further study reflecting the German health care setting was identified by hand-searching reference lists [69]. Table 9 gives an overview of the included studies.
Table 9

Comparison with previously published models on the cost-effectiveness of HPV vaccination in Germany

Study

Type of model

Type of economic analysis

Economic outcome measure

Diseases included

Vaccination strategy

Perspective

Duration of protection

Results (€/QALY or BCR)

Funding source

Present study

Dynamic

CEAa; CUA

ICER (€/QALY)a

CIN, cervical cancer, and genital warts

Bivalent and quadrivalent vaccination of females and males (2 and 3 doses; 50% coverage)

Health care payer and society

20 years

13,248–34,249 (bivalent vaccination of females)b; cost-saving to 14,711 (quadrivalent vaccination of females)b; 77,607–130,449 (additional bivalent vaccination of males)b; 68,118–117,240 (additional quadrivalent vaccination of males)b

Independent

Hillemanns et al. [69]

Static

CEAa; CUA

ICER (€/QALY)a

CIN, cervical cancer, and genital warts

Quadrivalent vaccination of females (3 doses; 80% coverage)

Health care payer

Lifelong

10,530

Industry

20 years

19,445

Kotsopoulos et al. [66]

Static

CBA

BCR

CIN, cervical cancer, vaginal cancer, vulvar cancer, anal cancer, and genital warts

Quadrivalent vaccination of females and males (2 doses; 55% coverage)

Society

Not reported

3.3 (vaccination of females); 0.3 (vaccination of male); 1.8 (vaccination of males and females)

Industry

Schobert et al. [67]

Dynamic

CEAa; CUA

ICER (€/QALY)a

CIN, cervical cancer, and genital warts

Quadrivalent vaccination of females (3 doses; 45–55% coverage)

Health care payer

Lifelong

5525

Industry

20 years

About 10,000

Soergel et al. [68]

Static

CEAa; CUA

ICER (€/QALY)a

Neonatal morbidity and mortality due to conisation-associated prematurity

Bivalent vaccination of females (3 doses; 30–90% coverage)

Not reported

Lifelong

43,505–47,885c

Independent

BCR benefit–cost ratio, CBA cost–benefit analysis, CEA cost-effectiveness analysis, CUA cost-utility analysis, CIN cervical intraepithelial neoplasia, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year

aCEA results are not presented in the table

bDepending on the perspective and the number of doses

cDepending on the utility values

Hillemanns et al. [69] used a static cohort model to estimate the cost-effectiveness of vaccinating 12-year-old girls alongside the existing cervical cancer screening programme compared to screening alone from the German health care payer perspective. They performed a cost-effectiveness analysis (CEA) and a cost-utility analysis (CUA) of the quadrivalent vaccine assuming a lifelong duration of protection. ICERs of the base case analysis, in which effects on CIN, cervical cancer, and genital warts in women were considered, were €15,684 per LY and €10,530 per QALY. ICERs increased to €16,689 per LY and €11,658 per QALY when genital warts were excluded. Restricting the duration of vaccine-induced protection to 20 years almost doubled the ICERs (€28,991 per LY; €19,445 per QALY).

Schobert et al. [67] presented results of both a CEA and a CUA using a dynamic transmission model that has already been used to evaluate the cost-effectiveness of HPV vaccination in other countries. They estimated the economic impact of vaccinating girls aged 12–17 years with three doses of the quadrivalent vaccine from a health care payer perspective considering HPV-associated diseases in women (CIN, cervical cancer and genitals warts) and men (genital warts). In the base case analysis, it was assumed that the vaccine provided lifelong protection, and the corresponding ICERs were €10,205 per LY and €5525 per QALY. The cost per QALY increased to about €10,000 when limiting the duration of protection to 20 years or excluding the protection of HPV6/11-associated diseases.

Kotsopoulos et al. [66] adopted a societal perspective and used a cost-benefit analysis (CBA) based on a static cohort model to quantify the economic impact of a 2-dose schedule of the quadrivalent vaccine in the prevention of HPV-related diseases in females and males (CIN, cervical, vaginal, vulvar and anal cancer, and genital warts). Female vaccination at the age of 12 years led to a benefit–cost ratio (BCR) of 3.3 meaning that €1 invested in HPV vaccination returns €3.3 in terms of prevented medical costs and productivity losses due to premature mortality. BCRs of male vaccination and universal vaccination (i.e. vaccination of males and females) were 0.3 and 1.8, respectively. However, the CBA was limited to a cost comparison (including cost-offsets) as health benefits were not valued in monetary units. Therefore, from a methodological perspective and in accordance with the commonly accepted definition of CBA [70], this study offers only a partial evaluation.

Soergel et al. [68] developed a static model based on the conisation-related neonatal morbidity and mortality in Germany. They conducted both a CEA and a CUA of HPV 16/18 vaccination with measuring the effects of HPV vaccination in terms of a reduced number of conisations and a corresponding decrease in conisation-associated neonatal morbidity and mortality. When vaccinating 12-year-old girls the cost per LY was €45,101 and the cost per QALY ranged from €43,505 to €47,885.

Discussion

Summary of key findings

In our model, vaccination of 12-year-old girls against HPV was associated with ICERs often considered as good value for money (below €50,000 per QALY). Additional protection against genital warts in females and males by the quadrivalent vaccine improved results substantially. This high impact of the HPV 6/11 component of the quadrivalent vaccine is largely due to the different time points at which prevention of HPV-associated outcomes occurs. Genital warts can be prevented relatively soon after vaccination, while the development of cervical cancer usually takes many years. Consequently, the discounting of future events leads to an emphasis on the prevention of genital warts and lowers the influence of avoided cervical cancer cases on the cost-effectiveness of HPV vaccination. In addition, the indirect benefits of preventing genital warts in males intensify the impact of the protection against HPV 6/11. However, when taking vaccine-specific cross-protection into account, estimated reduction in cervical cancer was higher for the bivalent vaccine than for the quadrivalent vaccine, despite a higher overall cost per QALY estimate. Inclusion of indirect costs lowered (improved) the ICERs by up to 40%. An even bigger improvement of the cost-effectiveness was shown by using a 2-dose schedule instead of a 3-dose schedule when assuming that two doses are as protective as three doses. This substantial improvement was triggered by the reduction in vaccination costs. By contrast, additional vaccination of boys resulted in mainly high or very high cost-effectiveness ratios, except for scenarios with low coverage in girls. This finding is in line with previous research on the cost-effectiveness of including males in HPV vaccination programmes in high-income countries [71]. However, male HPV-related cancers were not considered in our analyses, and the model was restricted to heterosexual transmission of HPV infection. Studies focussing on men who have sex with men (MSM) showed that HPV vaccination of MSM is likely to be a cost-effective intervention [72–74].

Comparison with other models

In other models reflecting the German health care setting, the cost per QALY of quadrivalent HPV vaccination with three doses ranged between €10,000 and €20,000 from a health care payer perspective when assuming a 20 years lasting duration of protection and considering effects on CIN, cervical cancer, and genital warts [67, 69]. Our estimate of €14,711 per QALY falls within this range of estimates. When adopting a societal perspective, quadrivalent HPV vaccination of 12-year-old girls with two doses resulted in cost savings in our model. This also compares well with previous findings [66]. In contrast, the study by Soergel et al. [68] allows no direct comparison with our estimates because it focussed on conisation-associated neonatal morbidity and mortality. However, Soergel et al. [68] showed that vaccinating girls against HPV 16/18 might even be cost-effective without considering the impact on cervical cancer.

Strengths and limitations

An important strength of our study is that we presented results for a wide range of scenarios varying the target group (female vaccination vs. no vaccination; female and male vaccination vs. female vaccination), coverage rate, and number of vaccine doses. Another strength is that we used a dynamic transmission model to estimate the cost-effectiveness of HPV vaccination in Germany. Compared to static models, which account only for direct effects of vaccination, dynamic models also capture indirect effects in terms of herd protection [75]. Furthermore, we included the impact of historical changes in participation rates of the cytological cervical cancer screening in Germany. This is one reason why our model might provide more accurate results than the dynamic model from Schobert et al. [67]. In addition, we applied a more comprehensive calibration approach than the aforementioned model and used age-specific epidemiological data for several calibration targets.

We acknowledge that our model also has several limitations. First, we did not include other cancers than cervical cancer. Other modelling studies showed that considering the impact on vaginal, vulvar, penile, anal, and head and neck cancer could improve the cost-effectiveness of HPV vaccination [76, 77]. However, our model reflects the goal of the current German HPV immunisation recommendation, which is defined (by STIKO) as the reduction in disease burden caused by cervical cancer. Second, our model evaluated the cost-effectiveness of the bivalent and quadrivalent vaccines, but did not include the new 9-valent HPV vaccine, which was introduced in Germany after completion of this study. However, we investigated the impact of including vaccine-specific cross-protection against non-vaccine high-risk HPV types in sensitivity analyses, and corresponding results might give an impression of the cost-effectiveness of higher-valent vaccines. We recommend including the 9-valent HPV vaccine in future modelling studies. Third, our model did not account for potential cross-protection of the bivalent vaccine against low-risk HPV types. Results of an ecological study suggest that there might be a moderate cross-protective effect of the bivalent vaccine against genital warts since the rates of genital warts have declined after the introduction of a national HPV vaccination programme using the bivalent vaccine in England [78]. In addition, a post hoc analysis of a clinical trial showed that the bivalent vaccine provides a moderate efficacy against persistent infection with low-risk HPV types [79]. Nevertheless, the underlying biological mechanisms of these findings have not yet been clarified conclusively. Fourth, in our base case analysis, we assumed a vaccination age of 12 years in order to ensure comparability with other studies although most girls in Germany have received the first dose in the age of 13 or 14 years [28]. However, the updated immunisation recommendation favours a younger vaccination age (from 9 years), which might impact future health and economic effects of HPV vaccination. Fifth, modelling of cervical cancer screening was based on cytological screening, which predominantly reflects the current screening practice in Germany. However, future changes to cervical cancer screening may involve primary HPV testing [80]. Sixth, input data on sexual behaviour were based on surveys from other European countries, and actual behaviour in Germany might differ from that in other countries. Seventh, due to the lack of German-specific utility values, the utility estimates we used in our model were taken from international studies with some of them resting on expert opinion. Furthermore, we assumed a baseline utility value of 1.0 in the absence of HPV-associated diseases, which might lead to a potential overestimation of HPV-related QALY losses. However, sensitivity analyses showed that variations in utilities had limited impact on the results. Eighth, since we used a stable population approach, our model did not take account of demographic trends and their implications.

Conclusions

Considering the often-cited threshold of €50,000 per QALY, our model results suggest that routine HPV vaccination of 12-year-old girls with three doses is likely to be cost-effective in Germany. Due to the additional impact on HPV 6/11-related diseases (mostly genital warts), the quadrivalent vaccine appeared to be more cost-effective than the bivalent vaccine, even when considering the higher cross-protection of the bivalent vaccine. Most of these findings are consistent with results predicted by previously published industry-funded models of HPV vaccination in Germany. Our model also showed that a 2-dose schedule of the quadrivalent vaccine could result in cost savings when assuming an equivalent level of protection and adopting a societal perspective. Additional vaccination of boys was found to be a cost-effective strategy in scenarios with low coverage in girls. However, there is a need for an extended version of this model that also accounts for the potential impact on non-cervical cancer types in both genders since the consideration of this aspect might lead to more favourable results regarding the additional vaccination of boys in scenarios with moderate or high coverage in girls.

Abbreviations

BCR: 

benefit–cost ratio

CBA: 

cost–benefit analysis

CEA: 

cost-effectiveness analysis

CIN: 

cervical intraepithelial neoplasia

CIS: 

carcinoma in situ

CPI: 

consumer price index

CUA: 

cost-utility analysis

DRG: 

diagnosis-related group

EBM: 

Einheitlicher Bewertungsmaßstab

FIGO: 

International Federation of Gynecology and Obstetrics

HPV: 

human papillomavirus

HUI: 

Health Utility Index

ICER: 

incremental cost-effectiveness ratio

QALY: 

quality-adjusted life year

MSM: 

men who have sex with men

RKI: 

Robert Koch Institute

SIRS: 

susceptible-infectious-recovered-susceptible

STIKO: 

Ständige Impfkommission (Standing Vaccination Committee)

Declarations

Authors’ contributions

OD and JH designed the study, developed the model, performed the data collection, carried out the analyses, and interpreted the results. OD conducted the interviews with clinical experts, performed the cost calculations, and drafted the manuscript. JH programmed and calibrated the model. AMK and YD helped to select the model input values and provided clinical expert advice. MEEK contributed to the study design and provided methodological expert advice. RTM and WG contributed to the study design, participated in the interpretation of the results, and supervised the project. All authors critically reviewed the initial draft. All authors read and approved the final manuscript.

Acknowledgements

We thank Matthias W. Beckmann (University Hospital Erlangen, Erlangen, Germany), Christian Dannecker (Hospital of the Ludwig-Maximilians-University München, München, Germany), Ingke Hagemann (abts + partner, Kiel, Germany), Peter Hillemanns (Hannover Medical School, Hannover, Germany), Karl U. Petry (Wolfsburg Clinic, Wolfsburg, Germany), Achim Schneider (Charité-Universitätsmedizin Berlin, Berlin, Germany) and the members of the German working group on cervical pathology and colposcopy for participating in the expert interviews. We also thank Julian Witte (Bielefeld University, Bielefeld, Germany) for his assistance in collecting unit cost data. We acknowledge support for the Article Processing Charge by the Deutsche Forschungsgemeinschaft and the Open Access Publication Fund of Bielefeld University.

Competing interests

OD and WG have conducted studies for Sanofi Pasteur MSD and GlaxoSmithKline unrelated to the current study. All other authors have no competing interests to declare.

Availability of data and materials

Not applicable.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Funding

The study was fully funded by Robert Koch Institute (Project Number: 1362/1-927).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Universitätsstraße 25, 33615 Bielefeld, Germany
(2)
Epidemiological and Statistical Methods Research Group, Helmholtz Centre for Infection Research, Braunschweig, Germany
(3)
Hannover Medical School, Hannover, Germany
(4)
German Centre for Infection Research, Site Hannover-Braunschweig, Hannover/Braunschweig, Germany
(5)
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
(6)
Centre for Infectious Disease Control, RIVM, Bilthoven, The Netherlands
(7)
Gynecologic Tumor Immunology, Clinic for Gynecology, Charité-Universitätsmedizin Berlin, Berlin, Germany
(8)
Praxis Löser/Kaden/Deleré/Knappe, Berlin, Germany
(9)
Immunisation Unit, Robert Koch Institute, Berlin, Germany
(10)
Department of Public Health Medicine, School of Public Health, Bielefeld University, Bielefeld, Germany

References

  1. Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–65.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113:3036–46.View ArticlePubMedGoogle Scholar
  3. Grulich AE, Jin F, Conway EL, Stein AN, Hocking J. Cancers attributable to human papillomavirus infection. Sex Health. 2010;7:244–52.View ArticlePubMedGoogle Scholar
  4. Dunne EF, Markowitz LE. Genital human papillomavirus infection. Clin Infect Dis. 2006;43:624–9.View ArticlePubMedGoogle Scholar
  5. Deleré Y, Wichmann O, Klug SJ, van der Sande M, Terhardt M, Zepp F, Harder T. The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis. Dtsch Arztebl Int. 2014;111:584–91.PubMedPubMed CentralGoogle Scholar
  6. Kash N, Lee MA, Kollipara R, Downing C, Guidry J, Tyring SK. Safety and efficacy data on vaccines and immunization to human papillomavirus. J Clin Med. 2015;4:614–33.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Lu B, Kumar A, Castellsagué X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis. 2011;11:13.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278–85.View ArticlePubMedGoogle Scholar
  9. Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, Langenberg A, Yen TS, Ralston R. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol. 1995;33:2058–63.PubMedPubMed CentralGoogle Scholar
  10. Ständige Impfkommission. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August 2014. Epidemiol Bull. 2014;34(2014):305–40.Google Scholar
  11. Ständige Impfkommission. Wissenschaftliche Begründung für die Änderung der Empfehlung zur Impfung gegen humane Papillomviren. Epidemiol Bull. 2014;35(2014):343–7.Google Scholar
  12. Horn J, Damm O, Kretzschmar MEE, Deleré Y, Wichmann O, Kaufmann AM, Garbe E, Krämer A, Greiner W, Mikolajczyk RT. Estimating the long-term effects of HPV vaccination in Germany. Vaccine. 2013;31:2372–80.View ArticlePubMedGoogle Scholar
  13. Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine. 2010;28:4091–102.View ArticlePubMedGoogle Scholar
  14. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28–41.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Zechmeister I, de Blasio BF, Garnett G, Neilson AR, Siebert U. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine. 2009;27:5133–41.View ArticlePubMedGoogle Scholar
  16. Canfell K, Barnabas R, Patnick J, Beral V. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer. 2004;91:530–6.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Elbasha EH, Dasbach EJ, Insinga RP. A multi-type HPV transmission model. Bull Math Biol. 2008;70:2126–76.View ArticlePubMedGoogle Scholar
  18. Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan S, Sherlaw-Johnson C, Drummond M. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer. 2007;96:143–50.View ArticlePubMedGoogle Scholar
  19. Schneider A, Hammerschmidt T, Schwarz TF, Rogoza RM, Ferko N, Siebert U. Long-term public health impact of vaccination against cervical cancer in Germany. Geburtshilfe Frauenheilkd. 2007;67:850–8.View ArticleGoogle Scholar
  20. Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry K, Krämer A, Siebert U. Entscheidungsanalytische Modellierung zur Evaluation der Langzeit-Effektivität und Kosten-Effektivität des Einsatzes der HPV-DNA-Diagnostik im Rahmen der Zervixkarzinomfrüherkennung in Deutschland. Köln: Deutsches Institut für Medizinische Dokumentation und Information; 2010.Google Scholar
  21. Mikolajczyk RT, Horn J, Damm O, Kaufmann AM, Kretzschmar MEE. Epidemiological study of anti-HPV-16/18 seropositivity and subsequent risk of HPV-16 and -18 infections. J Natl Cancer Inst. 2012;104:163.View ArticlePubMedGoogle Scholar
  22. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181:1911–9.View ArticlePubMedGoogle Scholar
  23. Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn L, Sherman ME, Xhenseval V, Herrero R, Hildesheim A. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst. 2010;102:1653–62.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of human papillomavirus (HPV) disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis. 2009;9:119.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Kerek-Bodden H, Altenhofen L, Brenner G. Durchführung einer versichertenbezogenen Untersuchung zur Inanspruchnahme der Früherkennung auf Zervixkarzinom in den Jahren 2002, 2003 und 2004 auf der Basis von Abrechnungsdaten. Berlin: Zentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland; 2009.Google Scholar
  26. Robert Koch-Institut. Gesundheit in Deutschland. Berlin: Robert Koch-Institut; 2006.Google Scholar
  27. Deleré Y, Böhmer MM, Walter D, Wichmann O. HPV vaccination coverage among women aged 18–20 years in Germany three years after recommendation of HPV vaccination for adolescent girls: results from a cross-sectional survey. Hum Vaccines Immunother. 2013;9:1706–11.View ArticleGoogle Scholar
  28. Poethko-Müller C, Buttmann-Schwelger N, KiGGS Study Group. Impfstatus und Determinanten der Impfung gegen humane Papillomviren (HPV) bei Mädchen in Deutschland. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57:869–77.View ArticlePubMedGoogle Scholar
  29. Remschmidt C, Fesenfeld M, Kaufmann AM, Deleré Y. Sexual behavior and factors associated with young age at first intercourse and HPV vaccine uptake among young women in Germany: implications for HPV vaccination policies. BMC Public Health. 2014;14:1248.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Rieck T, Feig M, Deleré Y, Wichmann O. Utilization of administrative data to assess the association of an adolescent health check-up with human papillomavirus vaccine uptake in Germany. Vaccine. 2014;32:5564–9.View ArticlePubMedGoogle Scholar
  31. Roggendorf H. Erste Erfahrungen zur Akzeptanz der HPV-Impfung. Monatsschr Kinderheilkd. 2009;157:982–5.View ArticleGoogle Scholar
  32. Stöcker P, Dehnert M, Schuster M, Wichmann O, Deleré Y. Human papillomavirus vaccine uptake, knowledge and attitude among 10th grade students in Berlin, Germany, 2010. Hum Vaccines Immunother. 2013;9:74–82.View ArticleGoogle Scholar
  33. de Vincenzo R, Conte C, Ricci C, Scambia G, Capelli G. Long-term efficacy and safety of human papillomavirus vaccination. Int J Womens Health. 2014;6:999–1010.View ArticlePubMedPubMed CentralGoogle Scholar
  34. David M, van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, van Damme P. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol. 2009;115:S1–6.View ArticlePubMedGoogle Scholar
  35. Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007;25:4324–33.View ArticlePubMedGoogle Scholar
  36. Beckmann MW, Mehlkorn G, Thiel F, Breuel C, Fasching PA, Ackermann S. Therapiefortschritte beim primären Zervixkarzinom. Dtsch Arztebl. 2005;102:A979–86.Google Scholar
  37. Dannecker C, Hantschmann P, Friese K. Stadienbezogene Therapie des Zervixkarzinoms. Gynäkologe. 2008;41:349.View ArticleGoogle Scholar
  38. Deutsche Krebsgesellschaft, Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, Arbeitsgemeinschaft Gynäkologische Onkologie. Diagnostik und Therapie des Zervixkarzinoms, AWMF 032/033 (S2k). Berlin: Deutsche Gesellschaft für Gynäkologie und Geburtshilfe; 2008.Google Scholar
  39. Hillemanns P. Manual Zervixkarzinom. 3rd ed. München: Tumorzentrum München und W. Zuckschwerdt Verlag GmbH; 2004.Google Scholar
  40. LAUER-TAXE. LAUER-FISCHER GmbH. http://www2.lauer-fischer.de. Accessed 17 Sept 2012.
  41. Petry KU, Breugelmans JG, Bénard S, Lamure E, Littlewood KJ, Hillemanns P. Cost of screening and treatment of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol. 2008;29:345–9.PubMedGoogle Scholar
  42. Hillemanns P, Breugelmans JG, Gieseking F, Bénard S, Lamure E, Littlewood KJ, Petry KU. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis. 2008;8:76.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Krankheitsartenstatistik (Versicherte der Allgemeinen Ortskrankenkassen). AOK-Bundesverband. 2008. http://www.gbe-bund.de. Accessed 17 Sept 2012.
  44. Bundesagentur für Arbeit. Arbeitsmarkt 2009. Nürnberg: Bundesagentur für Arbeit; 2010.Google Scholar
  45. Statistisches Bundesamt. Deutsche Wirtschaft 2010. Wiesbaden: Statistisches Bundesamt; 2011.Google Scholar
  46. Brisson M, Van de Velde N, de Wals P, Boily M. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007;25:5399–408.View ArticlePubMedGoogle Scholar
  47. Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making. 2007;27:414–22.View ArticlePubMedGoogle Scholar
  48. Institute of Medicine (U.S.). Commitee to Study Priorities for Vaccine Development. Vaccines for the 21st century: a tool for decisionmaking. Washington, D.C.: National Academy Press; 2000.Google Scholar
  49. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Allgemeine Methoden, Version 4.2. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen; 2015.Google Scholar
  50. von der Schulenburg JMG, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, Mittendorf T, Rebscher H, Schoeffski O, Vauth C, Volmer T, Wahler S, Wasem J, Weber C. German recommendations on health economic evaluation: third and updated version of the Hanover consensus. Value Health. 2008;11:539–44.View ArticleGoogle Scholar
  51. Damm O, Ultsch B. Health economic evaluation of vaccines. Gesundh ökon Qual Manag. 2015;20:163–72.View ArticleGoogle Scholar
  52. Dobson SRM, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309:1793–802.View ArticlePubMedGoogle Scholar
  53. Kreimer AR, Struyf F, Rosario-Raymundo Del, Rowena Maria, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David M, Wheeler CM, González P, Jiménez S, Lowy DR, Pinto LA, Porras C, Rodriguez AC, Safaeian M, Schiffman M, Schiller JT, Schussler J, Sherman ME, Bosch FX, Castellsague X, Chatterjee A, Chow S, Descamps D, Diaz-Mitoma F, Dubin G, Germar MJ, Harper DM, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica vaccine and PATRICIA trials. Lancet Oncol. 2015;16:775–86.View ArticlePubMedPubMed CentralGoogle Scholar
  54. Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Behre U, Suryakiran P, Thomas F, Struyf F. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccines Immunother. 2014;10:1155–65.View ArticleGoogle Scholar
  55. Forhan SE, Gottlieb SL, Sternberg MR, Xu F, Datta SD, McQuillan GM, Berman SM, Markowitz LE. Prevalence of sexually transmitted infections among female adolescents aged 14 to 19 in the United States. Pediatrics. 2009;124:1505–12.View ArticlePubMedGoogle Scholar
  56. Iftner T, Eberle S, Iftner A, Holz B, Banik N, Quint W, Straube A. Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: an epidemiological observational study. J Med Virol. 2010;82:1928–39.View ArticlePubMedGoogle Scholar
  57. Klug SJ, Hukelmann M, Hollwitz B, Düzenli N, Schopp B, Petry K, Iftner T. Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol. 2007;79:616–25.View ArticlePubMedGoogle Scholar
  58. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7:453–9.View ArticlePubMedGoogle Scholar
  59. Schneider A, Hoyer H, Lotz B, Leistritza S, Kühne-Heid R, Nindl I, Müller B, Haerting J, Dürst M. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer. 2000;89:529–34.View ArticlePubMedGoogle Scholar
  60. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, Haywood M, Elanko N, Coleman D, Yule R, Desai M. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer. 2004;91:942–53.PubMedPubMed CentralGoogle Scholar
  61. GEKID-Atlas. Gesellschaft der epidemiologischen Krebsregister in Deutschland. http://www.gekid.de. Accessed 17 Sept 2012.
  62. Castellsagué X, de Sanjose S, Aguado T, Louie KS, Bruni L, Muñoz N, Diaz M, Irwin K, Gacic M, Beauvais O, Albero G, Ferrer E, Byrne S, Bosch FX. HPV and cervical cancer in the 2007 report. Vaccine. 2007;25(Suppl 3):C1–230.Google Scholar
  63. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJF, Vaccarella S, Anh PTH, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJLM, Franceschi S. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366:991–8.View ArticlePubMedGoogle Scholar
  64. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomark Prev. 2005;14:1157–64.View ArticleGoogle Scholar
  65. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621–32.View ArticlePubMedGoogle Scholar
  66. Kotsopoulos N, Connolly MP, Remy V. Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework. Health Econ Rev. 2015;5:54.View ArticlePubMedGoogle Scholar
  67. Schobert D, Remy V, Schoeffski O. Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Econ Rev. 2012;2:19.View ArticlePubMedPubMed CentralGoogle Scholar
  68. Soergel P, Makowski L, Schippert C, Staboulidou I, Hille U, Hillemanns P. The cost efficiency of HPV vaccines is significantly underestimated due to omission of conisation-associated prematurity with neonatal mortality and morbidity. Hum Vaccines Immunother. 2012;8:243–51.View ArticleGoogle Scholar
  69. Hillemanns P, Petry KU, Largeron N, McAllister R, Tolley K, Büsch K. Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany. J Public Health. 2009;17:77–86.View ArticleGoogle Scholar
  70. Zarnke KB, Levine MA, O’Brien BJ. Cost-benefit analyses in the health-care literature: don’t judge a study by its label. J Clin Epidemiol. 1997;50:813–22.View ArticlePubMedGoogle Scholar
  71. Yahia MBBH, Jouin-Bortolotti A, Dervaux B. Extending the human papillomavirus vaccination programme to include males in high-income countries: a systematic review of the cost-effectiveness studies. Clin Drug Investig. 2015;35:471–85.View ArticleGoogle Scholar
  72. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010;10:845–52.View ArticlePubMedPubMed CentralGoogle Scholar
  73. Deshmukh AA, Chiao EY, Das P, Cantor SB. Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia. Vaccine. 2014;32:6941–7.View ArticlePubMedPubMed CentralGoogle Scholar
  74. Lin A, Ong KJ, Hobbelen P, King E, Mesher D, Edmunds WJ, Sonnenberg P, Gilson R, Bains I, Choi YH, Tanton C, Soldan K, Jit M. Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men. Clin Infect Dis. 2017;64:580–8.PubMedGoogle Scholar
  75. Ultsch B, Damm O, Beutels P, Bilcke J, Brüggenjürgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, Knol M, von Kries R, Kuhlmann A, Levy-Bruhl D, Perleth M, Postma M, Salo H, Siebert U, Wasem J, Wichmann O. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics. 2016;34:227–44.View ArticlePubMedGoogle Scholar
  76. de Kok IMCM, Habbema JDF, van Rosmalen J, van Ballegooijen M. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? Eur J Cancer. 2011;47:428–35.View ArticlePubMedGoogle Scholar
  77. Olsen J, Jørgensen TR. Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females. Cost Eff Resour Alloc. 2015;13:4.View ArticlePubMedPubMed CentralGoogle Scholar
  78. Canvin M, Sinka K, Hughes G, Mesher D. Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. Sex Transm Infect. 2016. doi:10.1136/sextrans-2016-052626.PubMedGoogle Scholar
  79. Szarewski A, Skinner SR, Garland SM, Romanowski B, Schwarz TF, Apter D, Chow SN, Paavonen J, Del Rosario-Raymundo MR, Teixeira JC, De Carvalho NS, Castro-Sanchez M, Castellsagué X, Poppe WAJ, De Sutter P, Huh W, Chatterjee A, Tjalma WA, Ackerman RT, Martens M, Papp KA, Bajo-Arenas J, Harper DM, Torné A, David MP, Struyf F, Lehtinen M, Dubin G. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis. 2013;208:1391–6.View ArticlePubMedPubMed CentralGoogle Scholar
  80. Luyten A, Buttmann-Schweiger N, Luyten K, Mauritz C, Reinecke-Lüthge A, Pietralla M, Meijer CJLM, Petry KU. Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme. Int J Cancer. 2014;135:1408–16.View ArticlePubMedGoogle Scholar
  81. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow S, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–14.View ArticlePubMedGoogle Scholar
  82. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27.View ArticleGoogle Scholar
  83. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter ST, Grace WK, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–43.View ArticlePubMedGoogle Scholar
  84. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang Y, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364:401–11.View ArticlePubMedPubMed CentralGoogle Scholar
  85. Brown DR, Kjaer SK, Sigurdsson K, Iversen O, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson S, Tang GWK, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis. 2009;199:926–35.View ArticlePubMedGoogle Scholar
  86. Szarewski A. HPV vaccine: cervarix. Expert Opin Biol Ther. 2010;10:477–87.View ArticlePubMedGoogle Scholar
  87. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604–15.View ArticlePubMedGoogle Scholar
  88. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36:778–92.View ArticlePubMedGoogle Scholar
  89. de Kok IMCM, van Ballegooijen M, Habbema JDF. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst. 2009;101:1083–92.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us